{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:53:05Z","timestamp":1768413185589,"version":"3.49.0"},"reference-count":114,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>A critical challenge in the age of advanced modulator therapies is to understand and determine how effectively chronic oxidative stress and oxidative stress-induced inflammation can be reversed and physiological balance restored when CFTR function is pharmacologically improved. The triple therapy with elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) suggests that CFTR activity in individuals with at least one F508del mutation can be partially restored to about 50% of normal levels. Although incomplete, the partial recovery of CFTR function has been shown to drastically lower sputum pathogen content, enhance microbiome diversity, and lower inflammation markers within the first year of treatment in adolescents and adults with cystic fibrosis. However, despite these advancements, residual airway infection, oxidative stress and inflammation persist, with levels similar to other chronic lung conditions, like non-CF bronchiectasis. This persistence highlights the necessity for innovative antioxidant and anti-inflammatory treatments, in particular for individuals with advanced lung disease. To address this issue, emerging multi-omics technologies offer valuable tools to investigate the impact of modulator therapies on various molecular pathways. By analyzing changes in gene expression, epigenetic modifications, protein profiles and metabolic processes in airway-derived samples, it could be possible to uncover the mechanisms driving persistent oxidative stress and inflammation. These insights could pave the way for identifying new therapeutic targets to fully restore airway health and overall physiological balance.<\/jats:p>","DOI":"10.3390\/antiox14030310","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T04:58:17Z","timestamp":1741064297000},"page":"310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["How Effectively Can Oxidative Stress and Inflammation Be Reversed When CFTR Function Is Pharmacologically Improved?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4858-4853","authenticated-orcid":false,"given":"Valeria Rachela","family":"Villella","sequence":"first","affiliation":[{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Castaldo","sequence":"additional","affiliation":[{"name":"SC di Pneumologia e UTSIR, AORN Santobono-Pausilipon, 80122 Naples, Italy"},{"name":"Dipartimento di Scienze Mediche Traslazionali, Sezione di Pediatria, Universit\u00e0 di Napoli Federico II, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-7315","authenticated-orcid":false,"given":"Filippo","family":"Scial\u00f2","sequence":"additional","affiliation":[{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"},{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 di Napoli Federico II, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Castaldo","sequence":"additional","affiliation":[{"name":"CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy"},{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 di Napoli Federico II, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.med.58.071905.105316","article-title":"Airway surface dehydration in cystic fibrosis: Pathogenesis and therapy","volume":"58","author":"Boucher","year":"2007","journal-title":"Annu. Rev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","article-title":"CFTR function and prospects for therapy","volume":"77","author":"Riordan","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.23736\/S0026-4946.19.05506-3","article-title":"Mutation-specific therapies and drug repositioning in cystic fibrosis","volume":"71","author":"Villella","year":"2019","journal-title":"Minerva Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Carnovale, V., and Scial\u00f2, F. (2022). Cystic Fibrosis Patients with F508del\/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor\/Tezacaftor\/Ivacaftor Treatment. J. Clin. Med., 11.","DOI":"10.3390\/jcm11236900"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: A worldwide analysis of CFTR mutations\u2014Correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum. Mutat."},{"key":"ref_10","first-page":"45","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application. Nature reviews","volume":"16","author":"Cutting","year":"2015","journal-title":"Genetics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/109065701750168725","article-title":"Prevalence of cystic fibrosis mutations in Israeli Jews","volume":"5","author":"Orgad","year":"2001","journal-title":"Genet. Test."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41419-019-1500-x","article-title":"Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis","volume":"10","author":"Villella","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_14","unstructured":"Vicente-Santamar\u00eda, S., and Torres-Guerrero, M.E. (Gastroenterol. Hepatol., 2024). Assessment of cystic fibrosis related liver disease in a pediatric cohort, Gastroenterol. Hepatol., in Press."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gharib, S.A., and Vemireddy, R. (2024). Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-76722-1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1172\/JCI73469","article-title":"Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure","volume":"124","author":"Henderson","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nm1028","article-title":"Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice","volume":"10","author":"Mall","year":"2004","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"276ra27","DOI":"10.1126\/scitranslmed.3010525","article-title":"Oxidation increases mucin polymer cross-links to stiffen airway mucus gels","volume":"7","author":"Yuan","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.1073\/pnas.2634339100","article-title":"Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium","volume":"100","author":"Coakley","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","article-title":"Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung","volume":"487","author":"Pezzulo","year":"2012","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.23736\/S0026-4946.19.05511-7","article-title":"Personalization of therapies in rare diseases: A translational approach for the treatment of cystic fibrosis","volume":"71","author":"Villella","year":"2019","journal-title":"Minerva Pediatr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cell.2011.11.024","article-title":"Correction of both NBD1 energetics and domain interface is required to restore \u0394F508 CFTR folding and function","volume":"148","author":"Rabeh","year":"2012","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cell.2011.11.023","article-title":"Requirements for efficient correction of \u0394F508 CFTR revealed by analyses of evolved sequences","volume":"148","author":"Mendoza","year":"2012","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin. Chest Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Robinson","year":"2023","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study","volume":"206","author":"Mall","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: A 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jcf.2019.11.002","article-title":"Intestinal organoids for Cystic Fibrosis research","volume":"19","author":"Lefferts","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"108180","DOI":"10.1016\/j.isci.2023.108180","article-title":"In silico analysis and theratyping of an ultra-rare CFTR genotype (W57G\/A234D) in primary human rectal and nasal epithelial cells","volume":"26","author":"Kleinfelder","year":"2023","journal-title":"iScience"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1165\/rcmb.2019-0384OC","article-title":"Assessing Human Airway Epithelial Progenitor Cells for Cystic Fibrosis Cell Therapy","volume":"63","author":"Lee","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12931-023-02535-x","article-title":"L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: In vitro guided personalized therapy of non-F508del patients","volume":"24","author":"Castelli","year":"2023","journal-title":"Respir. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: From disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kleinfelder, K., and Villella, V.R. (2023). Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210358"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"00127-2017-ERR","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jcf.2024.05.004","article-title":"Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)","volume":"23","author":"Ciobanu","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Scial\u00f2, F., and Cernera, G. (2024). Effect of CFTR Modulators on Oxidative Stress and Autophagy in Non-CFTR-Expressing Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910360"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hoppe, J.E., and Kasi, A.S. (2024). Vanzacaftor-tezacaftor-deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): An analysis from a single-arm, phase 3 trial. Lancet Respir. Med.","DOI":"10.1016\/S2213-2600(24)00407-7"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Keating, C., and Yonker, L.M. (2024). Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): Results from two randomised, active-controlled, phase 3 trials. Lancet Respir. Med.","DOI":"10.1016\/S2213-2600(24)00411-9"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids","volume":"21","author":"Spelier","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00038114","article-title":"Oxidative stress in cystic fibrosis lung disease: An early event, but worth targeting?","volume":"44","author":"Hector","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1089\/ars.2014.6012","article-title":"Cystic fibrosis-related oxidative stress and intestinal lipid disorders","volume":"22","author":"Kleme","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Corteselli, E., and Aboushousha, R. (2022). S-Glutathionylation-Controlled Apoptosis of Lung Epithelial Cells; Potential Implications for Lung Fibrosis. Antioxidants, 11.","DOI":"10.3390\/antiox11091789"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/ars.2011.4198","article-title":"Glutathione redox control of asthma: From molecular mechanisms to therapeutic opportunities","volume":"17","author":"Fitzpatrick","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.rmed.2008.09.013","article-title":"The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI\/ARDS patient treated with N-acetylcysteine","volume":"103","author":"Moradi","year":"2009","journal-title":"Respir. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/emboj\/cdg194","article-title":"CFTR directly mediates nucleotide-regulated glutathione flux","volume":"22","author":"Kogan","year":"2003","journal-title":"EMBO J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.freeradbiomed.2017.09.028","article-title":"Oxidative stress in early cystic fibrosis lung disease is exacerbated by airway glutathione deficiency","volume":"113","author":"Dickerhof","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1128\/IAI.72.4.2045-2051.2004","article-title":"Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection","volume":"72","author":"Day","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.freeradbiomed.2020.03.001","article-title":"Myeloperoxidase inhibition decreases morbidity and oxidative stress in mice with cystic fibrosis-like lung inflammation","volume":"152","author":"Dickerhof","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Chen, J., and Kinter, M. (2008). Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003367"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1172\/JCI96273","article-title":"Clinically-approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia","volume":"129","author":"Borcherding","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Di Pietro, C., and \u00d6z, H.H. (2020). Targeting the Heme Oxygenase 1\/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01059"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.2353\/ajpath.2009.090166","article-title":"Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis","volume":"175","author":"Caldwell","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Amato, F., and Castaldo, A. (2021). Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245302"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Caterino, M., and Fedele, R. (2023). Lipidomic alterations in human saliva from cystic fibrosis patients. Sci. Rep., 13.","DOI":"10.1038\/s41598-022-24429-6"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cmet.2021.06.006","article-title":"Sphingolipids in metabolic disease: The good, the bad, and the unknown","volume":"33","author":"Green","year":"2021","journal-title":"Cell Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"109928","DOI":"10.1016\/j.cellsig.2021.109928","article-title":"Myriocin modulates the altered lipid metabolism and storage in cystic fibrosis","volume":"81","author":"Signorelli","year":"2021","journal-title":"Cell Signal."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Guerini, M., and Condr\u00f2, G. (2022). N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020217"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcf.2014.08.008","article-title":"Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial","volume":"14","author":"Conrad","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_69","first-page":"CD009422","article-title":"Vitamin E supplementation in people with cystic fibrosis","volume":"9","author":"Okebukola","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Traber, M.G., and Leonard, S.W. (2022). \u03b1-Tocopherol Pharmacokinetics in Adults with Cystic Fibrosis: Benefits of Supplemental Vitamin C Administration. Nutrients, 14.","DOI":"10.3390\/nu14183717"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.advms.2018.04.001","article-title":"Vitamin E status and its determinants in patients with cystic fibrosis","volume":"63","author":"Sapiejka","year":"2018","journal-title":"Adv. Med. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.201303-0427OC","article-title":"Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial","volume":"188","author":"Griese","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1945892419878315","article-title":"Efficacy of Glutathione for Patients With Cystic Fibrosis: A Meta-analysis of Randomized-Controlled Studies","volume":"34","author":"Zhao","year":"2020","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_74","first-page":"1075","article-title":"Early pulmonary inflammation in infants with cystic fibrosis","volume":"151","author":"Khan","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/ppul.20294","article-title":"Lower airway inflammation in infants with cystic fibrosis detected by newborn screening","volume":"40","author":"Armstrong","year":"2005","journal-title":"Pediatr. Pulmonol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/rccm.201908-1558ED","article-title":"Cystic Fibrosis Lung Disease and Immunometabolism. Targeting the NLRP3 Inflammasome","volume":"200","author":"Cantin","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ghigo, A., and Prono, G. (2021). Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041952"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1183\/09031936.02.00229202","article-title":"Mechanisms and markers of airway inflammation in cystic fibrosis","volume":"19","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"00312","DOI":"10.1183\/23120541.00312-2024","article-title":"Neutrophil extracellular traps are associated with airways inflammation and increased severity of lung disease in cystic fibrosis","volume":"10","author":"Law","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"106144","DOI":"10.1016\/j.rmed.2020.106144","article-title":"Extracellular DNA in sputum is associated with pulmonary function and hospitalization in patients with cystic fibrosis","volume":"172","author":"Piva","year":"2020","journal-title":"Respir. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wellems, D., and Hu, Y. (2023). Loss of CFTR function in macrophages alters the cell transcriptional program and delays lung resolution of inflammation. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1242381"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Da Silva Cunha, A.L., and Blanter, M. (2024). Inhibiting CFTR through inh-172 in primary neutrophils reveals CFTR-specific functional defects. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-82535-z"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bruscia, E.M., and Zhang, P.X. (2012). Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator\u2212\/\u2212 mice. Am. J. Respir. Cell Mol. Biol., 46.","DOI":"10.1165\/ajrcmb.46.4.561"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2174\/1389450116666150416114514","article-title":"Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease","volume":"16","author":"Sirinupong","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1002\/jcp.26497","article-title":"Histone methylation and acetylation in macrophages as a mechanism for regulation of inflammatory responses","volume":"233","author":"Daskalaki","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2213-2600(19)30335-2","article-title":"Cystic fibrosis lung disease and bronchiectasis","volume":"8","author":"Chalmers","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Petrocheilou, A., and Moudaki, A. (2022). Inflammation and Infection in Cystic Fibrosis: Update for the Clinician. Children, 9.","DOI":"10.3390\/children9121898"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Scialo, F., and Amato, F. (2021). Lung Microbiome in Cystic Fibrosis. Life, 11.","DOI":"10.3390\/life11020094"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcf.2020.12.022","article-title":"Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis","volume":"20","author":"Frey","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.25190","article-title":"Bacteriophage therapy for infections in CF","volume":"56","author":"Chan","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e121468","DOI":"10.1172\/jci.insight.121468","article-title":"Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis","volume":"3","author":"Launspach","year":"2018","journal-title":"JCI Insight"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Durfey, S.L., and Pipavath, S. (2021). Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections. mBio, 12.","DOI":"10.1128\/mbio.03148-21"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Saluzzo, F., and Riberi, L. (2022). CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells, 11.","DOI":"10.3390\/cells11071243"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13223-023-00822-2","article-title":"The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis","volume":"19","author":"Mehta","year":"2023","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jcf.2019.08.023","article-title":"Adrenal function in cystic fibrosis","volume":"18","author":"Rayas","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1513\/AnnalsATS.202401-118ED","article-title":"STOP Using Corticosteroids in Cystic Fibrosis Pulmonary Exacerbations","volume":"21","author":"Parkins","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcf.2013.12.009","article-title":"A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis","volume":"13","author":"Konstan","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cct.2018.07.014","article-title":"EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis\u2014Study design and patient demographics","volume":"72","author":"Elborn","year":"2018","journal-title":"Contemp. Clin. Trials"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1189\/jlb.0412188","article-title":"Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection","volume":"92","author":"Bonfield","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"L677","DOI":"10.1152\/ajplung.00030.2009","article-title":"Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences","volume":"297","author":"Vandivier","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jcf.2017.03.011","article-title":"CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis","volume":"16","author":"Tarique","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Pierdomenico, A.M., and Patruno, S. (2017). microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-14055-y"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Isopi, E., and Mattoscio, D. (2020). Resolvin D1 Reduces Lung Infection and Inflammation Activating Resolution in Cystic Fibrosis. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00581"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41419-020-02985-x","article-title":"NLRP3 inflammasome in endothelial dysfunction","volume":"11","author":"Bai","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1164\/rccm.201905-1013OC","article-title":"Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis","volume":"200","author":"McElvaney","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/imm.13336","article-title":"NLR family pyrin domain containing 3 (NLRP3) and caspase 1 (CASP1) modulation by intracellular Cl- concentration","volume":"163","author":"Clauzure","year":"2021","journal-title":"Immunology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1164\/rccm.201906-1206OC","article-title":"Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis","volume":"201","author":"Nichols","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e00394","DOI":"10.1002\/prp2.394","article-title":"Ajulemic acid: Potential treatment for chronic inflammation","volume":"6","author":"Burstein","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41591-018-0099-2","article-title":"Thymosin \u03b11 represents a potential potent single-molecule-based therapy for cystic fibrosis","volume":"24","author":"Romani","year":"2018","journal-title":"Nat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e144983","DOI":"10.1172\/JCI144983","article-title":"Anakinra restores cellular proteostasis by coupling mitochondrial redox balance to autophagy","volume":"132","author":"Renga","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jconrel.2022.11.043","article-title":"Pulmonary drug delivery technology enables anakinra repurposing in cystic fibrosis","volume":"353","author":"Puccetti","year":"2023","journal-title":"J. Control Release"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.4161\/auto.25517","article-title":"Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR","volume":"9","author":"Villella","year":"2013","journal-title":"Autophagy"}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/14\/3\/310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:46:51Z","timestamp":1760028411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/14\/3\/310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":114,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["antiox14030310"],"URL":"https:\/\/doi.org\/10.3390\/antiox14030310","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}